Pulmonary Complications of Immunotherapy

August 19, 2026

Target Audience

The series is designed for pathologists, pulmonologists, radiologists, rheumatologists, and other health providers who care for people with ILD.

Learning Objectives

  1. Review the basics of the immune system
  2. Learn the importance of the immune system in the development of cancer
  3. Review the role of immunotherapy in cancer
  4. Review the pulmonary complications of immunotherapy

 

 

 

 

 

Course summary

Available credit: 
  • 1.00 ABIM Medical Knowledge
  • 1.00 ABPATH Lifelong Learning
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
    • 1.00 ANCC Pharmacology
  • 1.00 Participation
Course opens: 
08/19/2026
Course expires: 
08/26/2026
Event starts: 
08/19/2026 - 7:00am EDT
Event ends: 
08/19/2026 - 8:00am EDT
Add to calendar: 
Rating: 
0

Time

Didactic Presentation / Case Discussion

Presenter 

7:00am-7:05am

Announcements and Introductions

Aliaa Barakat, PhD
Robert Hallowell, MD

7:05am-7:25am

Pulmonary Complications of Immunotherapy

Benjamin Medoff, MD

7:25am-8:00am

Case Presentation and Discussion

Grace Peloquin, MD

  8:00am

Closing Remarks

Aliaa Barakat, PhD

Virtual Meeting
Boston, MA
United States

Medical Director:Robert Hallowell, MD

Speaker: Benjamin Medoff, MD 

Principal Investigator: Aliaa Barakat, PhD

Discussion Facilitator: Grace Peloquin, MD

Disclosure Policy
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.

The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company.

Name

Disclosure of Relevant Financial Relationships

Aliaa Barakat, PhD

 Dr. Barakat has no relevant financial relationships to disclose.

Katharine Black, MD

 Dr. Black has no relevant financial relationships to disclose.

Fiona Gibbons, MD

 Dr. Gibbons has no relevant financial relationships to disclose.

Leo Ginns, MD

 Dr. Ginns is a researcher for United Therapeutics.

Robert Hallowell, MD

Dr. Hallowell is on the advisory board and an investigator for Boehringer Ingelheim. He is a consultant and an investigator for Vicore. He also is a consultant for Merck and receives authorship fees from Up-to-date and Dynamed.

 Benjamin Medoff, MDDr. Medoff is on the advisory board for Apogee, Regeneron, Sanofi. He also receives research support from Regeneron and Sanofi.

Sydney Montesi, MD

Dr. Montesi is a consultant and on the clinical ajudication committee for AbbVie. She is also a consultant for Accendatech, and Mediar Therapeutics. She receives research funding from Boehrnger Ingelheim, and Pliant Therapeutics via her institution. She also receives authorship fees from Wolters Kluwer.

Grace Peloquin, MD

Dr. Peloquin has no relevant financial relationships to disclose.

Barry Shea, MD

Dr. Shea is an investigator for Boehringer Ingelheim and Bristol Myers Squibb. He is a consultant for Contineum Therapeutics, Radius Health, and United Therapeutis.

Accreditor Disclosure
Michael Burk, Senior Operations Manager for Boston University Chobanian & Avedisian School of Medicine Center for Continuing Education has no relevant financial relationships to disclose.

Off-Label Discussion
Dr. Medoff plans on discussing unlabeled/investigational uses of many immunosuppressant drugs and some antifibrotic drugs used to treat ILD. 

All of the relevant financial relationships listed for these individuals have been mitigated.


In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and the ILD Collaborative. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology Maintenance of Certification (MOC) Part 2 Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Pathology’s (ABPath) Maintenance of Certification (MOC) program. Credit type: Lifelong Learning (CME)

By participating and claiming credit, you grant the Center for Continuing Education permission to submit your information to the ACCME, the conduit to the ABIM and ABPath.

Physician Accreditation
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Accreditation
Nursing Contact Hours: 1.0, all of which is eligible for pharmacology credit. 

 

Available Credit

  • 1.00 ABIM Medical Knowledge
  • 1.00 ABPATH Lifelong Learning
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
    • 1.00 ANCC Pharmacology
  • 1.00 Participation
Please login or register to take this course.